RBAK (RB-associated KRAB zinc finger) was reported to be upregulated in NSCLC [105], cholangiocarcinoma [106], and prostate cancer (Figure 4), likely due to a decreased level of its upstream negative regulator—miR135a [107]. Here, RBAK is linked to prostate cancer.